Lotte Biologics Names James Park Former GC Cell CEO As New CEO
Dec 02, 2024
|
James Park earned a bachelor's degree in chemical engineering at the University of California, Davis, and a master's degree in industrial engineering at Columbia University. Since then, he has served as the head of global pharmaceutical company Merck, Bristol Myersquip (BMS), and Samsung Biologics' global sales center (vice president) and until recently served as the CEO of GC Cell, a company specializing in cell and gene therapy (CGT).
In particular, he participated in due diligence in the field of pharmaceutical process development and quality control (CMC) from the preclinical stage to commercialization during his tenure at BMS, overseeing business development including licensing out and mergers and acquisitions (M&A), and signed orders with various global companies at Samsung Biologics. Recently, it accelerated its global expansion by leading a technology transfer contract for GC Cell's flagship auto-derived anti-cancer immune cell therapy 'Imuncell-LC stock'.
A company official said, "We expect that the recruitment of James Park will pave the way for a turnaround to target the global market while providing a bridgehead to smoothly connect Korean and U.S. executives and employees."The new CEO is the right person with expertise in overall management and excellent leadership in global orders."
James Park will be officially appointed as the new CEO after an extraordinary general meeting of shareholders and a board of directors in the future.
compact@sportschosun.com
